-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Data treasure statistics show that in the past 5 trading days (March 29 to April 6), a total of 110 companies in Shanghai and Shenzhen have been investigated by more than 20 institutions, including many pharmaceutical and biological industry company
.
Among the stocks surveyed by more than 20 institutions, Boji Pharmaceutical has performed well, and has received research from more than 60 institutions.
In the past 5 days, the net inflow of funds has exceeded 100 million yuan, reaching 134 million yuan, and the main net inflow of funds ranks first
.
On April 5th, Boji Pharmaceutical released a record of investor relations activities.
On April 2nd, the company received Cinda Securities, TEDA Manulife, Haifutong, Industrial Fund, Donghai Fund, Hengyue Fund, Great Wall Fund, Taiping Fund, etc.
Research by several institutions
.
In the communication and interaction session, the agency mainly focused on the company's business development, the reasons for the increase in performance, the number of orders in hand, the impact of traditional Chinese medicine policies on the company's business, the current situation of Shaoxing's CDMO and future plans
.
Among them, in terms of business layout, the company said that although it has been deploying integrated capabilities in the past few years, clinical practice is still the top priority, and it has been increasing investment in clinical talents in the past two years
.
The clinical business is regarded as the company's particularly advantageous and competitive business.
In the clinical business, it focuses on the development of liver disease, digestion, oncology and traditional Chinese medicine business.
The company will develop its competitive advantages in subdivided fields based on clinical practice, and synergistically develop preclinical and CDMO business
.
In response to the impact of traditional Chinese medicine policies on the company's business, Boji Pharmaceutical said that traditional Chinese medicine has always been a characteristic field of the company.
There are about 20 major clinical projects of traditional Chinese medicine under research every year, and the total revenue of traditional Chinese medicine accounts for about 20%
.
With the increasing support of the state for traditional Chinese medicine, the enthusiasm for research and development of traditional Chinese medicine has increased.
The company will also strengthen the undertaking of traditional Chinese medicine projects in business this year, and it is believed that orders will increase
.
In addition, in 2021, the company will integrate the clinical and pre-clinical business of traditional Chinese medicine into Xinglin Traditional Chinese Medicine, a wholly-owned subsidiary
.
On April 2, Boji Pharmaceutical also released a record of investor relations activities.
On April 1, the company obtained surveys from more than 60 institutions including Shanghai Securities, Huafu, and Wells Fargo
.
In this round of communication and interaction, the organization has 11 opinions on the company's orders in hand, business segments, team building and other measures in the company's transformation process, the current progress of the company's "3CL" project, CDMO production capacity, and future layout and planning.
question was asked
.
In terms of future layout and planning, Boji Pharmaceutical stated that there are three aspects: first, the company is mainly clinical, and will continue to give full play to its clinical advantages in the future to undertake more orders for innovative drugs; second, in recent years, the company It has been strengthening the construction of personnel teams, and has done many projects in the field of liver disease and digestion, which are highly recognized by customers.
In the past two years, it has focused on the field of oncology and recruited talents in the field of oncology.
Third, traditional Chinese medicine has always been the company's characteristic.
In order to make better use of the company's advantages in the field of traditional Chinese medicine, the company will integrate the clinical and preclinical business of traditional Chinese medicine into the wholly-owned subsidiary Xinglin Traditional Chinese Medicine in 2021.
All-in-one service company
.
According to public information, Boji Medicine's main business includes clinical research services, pre-clinical research services, technical achievement transformation services, other consulting services, and pre-clinical independent research and development
.
Boji Pharmaceutical released a performance forecast on the evening of January 23, saying that the net profit attributable to shareholders of listed companies in 2021 is expected to be 37 million to 48 million yuan, a year-on-year increase of 117.
79% to 182.
54%; performance changes are mainly due to the company during the reporting period.
Steady progress of research projects
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among the stocks surveyed by more than 20 institutions, Boji Pharmaceutical has performed well, and has received research from more than 60 institutions.
In the past 5 days, the net inflow of funds has exceeded 100 million yuan, reaching 134 million yuan, and the main net inflow of funds ranks first
.
On April 5th, Boji Pharmaceutical released a record of investor relations activities.
On April 2nd, the company received Cinda Securities, TEDA Manulife, Haifutong, Industrial Fund, Donghai Fund, Hengyue Fund, Great Wall Fund, Taiping Fund, etc.
Research by several institutions
.
In the communication and interaction session, the agency mainly focused on the company's business development, the reasons for the increase in performance, the number of orders in hand, the impact of traditional Chinese medicine policies on the company's business, the current situation of Shaoxing's CDMO and future plans
.
Among them, in terms of business layout, the company said that although it has been deploying integrated capabilities in the past few years, clinical practice is still the top priority, and it has been increasing investment in clinical talents in the past two years
.
The clinical business is regarded as the company's particularly advantageous and competitive business.
In the clinical business, it focuses on the development of liver disease, digestion, oncology and traditional Chinese medicine business.
The company will develop its competitive advantages in subdivided fields based on clinical practice, and synergistically develop preclinical and CDMO business
.
In response to the impact of traditional Chinese medicine policies on the company's business, Boji Pharmaceutical said that traditional Chinese medicine has always been a characteristic field of the company.
There are about 20 major clinical projects of traditional Chinese medicine under research every year, and the total revenue of traditional Chinese medicine accounts for about 20%
.
With the increasing support of the state for traditional Chinese medicine, the enthusiasm for research and development of traditional Chinese medicine has increased.
The company will also strengthen the undertaking of traditional Chinese medicine projects in business this year, and it is believed that orders will increase
.
In addition, in 2021, the company will integrate the clinical and pre-clinical business of traditional Chinese medicine into Xinglin Traditional Chinese Medicine, a wholly-owned subsidiary
.
On April 2, Boji Pharmaceutical also released a record of investor relations activities.
On April 1, the company obtained surveys from more than 60 institutions including Shanghai Securities, Huafu, and Wells Fargo
.
In this round of communication and interaction, the organization has 11 opinions on the company's orders in hand, business segments, team building and other measures in the company's transformation process, the current progress of the company's "3CL" project, CDMO production capacity, and future layout and planning.
question was asked
.
In terms of future layout and planning, Boji Pharmaceutical stated that there are three aspects: first, the company is mainly clinical, and will continue to give full play to its clinical advantages in the future to undertake more orders for innovative drugs; second, in recent years, the company It has been strengthening the construction of personnel teams, and has done many projects in the field of liver disease and digestion, which are highly recognized by customers.
In the past two years, it has focused on the field of oncology and recruited talents in the field of oncology.
Third, traditional Chinese medicine has always been the company's characteristic.
In order to make better use of the company's advantages in the field of traditional Chinese medicine, the company will integrate the clinical and preclinical business of traditional Chinese medicine into the wholly-owned subsidiary Xinglin Traditional Chinese Medicine in 2021.
All-in-one service company
.
According to public information, Boji Medicine's main business includes clinical research services, pre-clinical research services, technical achievement transformation services, other consulting services, and pre-clinical independent research and development
.
Boji Pharmaceutical released a performance forecast on the evening of January 23, saying that the net profit attributable to shareholders of listed companies in 2021 is expected to be 37 million to 48 million yuan, a year-on-year increase of 117.
79% to 182.
54%; performance changes are mainly due to the company during the reporting period.
Steady progress of research projects
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
